Key Points
- Director Paul Isaac bought 20,000 shares at $2.24 each for a total of $44,800, raising his stake to 2,786,557 shares (a 0.72% increase) valued at about $6.24 million.
- Stereotaxis (NYSEAMERICAN:STXS) trades near $2.29 with a market cap of $208.6 million and a 52-week range of $1.54–$3.59 (50-day MA $2.90, 200-day MA $2.54).
- Analysts have a consensus Buy rating with an average price target of $4.00, while institutional investors own about 45.35% of the company after several recent new stakes and increases.
Stereotaxis Inc. (NYSEAMERICAN:STXS - Get Free Report) Director Paul Isaac purchased 20,000 shares of the business's stock in a transaction on Friday, November 14th. The stock was purchased at an average price of $2.24 per share, with a total value of $44,800.00. Following the purchase, the director owned 2,786,557 shares of the company's stock, valued at approximately $6,241,887.68. The trade was a 0.72% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Stereotaxis Price Performance
Stereotaxis stock opened at $2.29 on Wednesday. The company's 50-day moving average is $2.90 and its 200-day moving average is $2.54. The firm has a market capitalization of $208.55 million, a PE ratio of -7.90 and a beta of 1.65. Stereotaxis Inc. has a fifty-two week low of $1.54 and a fifty-two week high of $3.59.
Analyst Ratings Changes
A number of research analysts recently weighed in on the company. Roth Capital reissued a "buy" rating and set a $4.00 target price on shares of Stereotaxis in a report on Wednesday, November 12th. UBS Group set a $4.00 price objective on shares of Stereotaxis in a report on Wednesday, November 5th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, Stereotaxis presently has a consensus rating of "Buy" and an average price target of $4.00.
View Our Latest Research Report on STXS
Institutional Investors Weigh In On Stereotaxis
Hedge funds and other institutional investors have recently modified their holdings of the company. Qube Research & Technologies Ltd bought a new stake in Stereotaxis in the 3rd quarter valued at about $295,000. Moneta Group Investment Advisors LLC acquired a new stake in Stereotaxis during the third quarter worth approximately $43,000. Lagoda Investment Management L.P. increased its stake in Stereotaxis by 0.4% during the 3rd quarter. Lagoda Investment Management L.P. now owns 4,707,400 shares of the company's stock worth $14,640,000 after acquiring an additional 19,500 shares during the period. Bank of America Corp DE raised its holdings in Stereotaxis by 12.0% in the 3rd quarter. Bank of America Corp DE now owns 63,114 shares of the company's stock valued at $196,000 after acquiring an additional 6,742 shares in the last quarter. Finally, Boothbay Fund Management LLC bought a new stake in shares of Stereotaxis during the 3rd quarter valued at $54,000. Institutional investors and hedge funds own 45.35% of the company's stock.
About Stereotaxis
(
Get Free Report)
Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
